SKITUDE
4.6.2019 16:46:10 CEST | Business Wire | Press release
The merger of Skitude, the largest network of skiing apps, and the Skioo innovative skipass technology, which provides access to ski resorts with a single card and no waiting in line, aims to optimise sales channels for the more than 150 partnering ski resorts for the upcoming season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604005775/en/
Alongside may other advantages, the strategy will consist of using post-payment systems to facilitate the user’s skiing experience, streamlining their access to the slopes, and helping the ski resorts position their products on their online platform.
“We are working so that skiers can purchase a ski pass ahead of time and load the ticket on their RFID card, or validate beforehand using a credit card, easily from their mobile on”, explained Skitude CEO Marc Bigas. “These principles of convenience and post-payment are already well-known thanks to popular services like Uber”, he added.
As a result, Skitude Chairman Yngve Tvedt explains, the combined digital platform will add a new dimension to the ski industry with a digital journey that is simpler and fun.
Thus, Tvedt assures, Skitude is participating in the “digitalisation of the sector” and agrees with Marc Bigas that this experience will offer “more convenience to the skier” as well as “powerful solutions for the mobile sales channels and marketing services” that will help ski resorts stay better connected with the needs of their current and potential customers.
New challenges
The merger of the two companies is also aimed at finding a way to push back against the stagnation of users in the industry, one of the sector's main challenges. “We are setting off on a journey to meet challenges using technology”, the company’s CEO stated, adding that the experience built up by both Skitude and Skioo over the years will become “valuable information for ski resorts”.
It is worth noting that the Girona-based company has always been committed to interacting with users “before, during and after their visit”, which, according to Bigas, “strengthens the competitiveness of the industry and enables it to continue moving forward”.
A community of more than 1.3 million skiers
The Skitude community is currently made up of more than 1.3 million skiers who have used the free applications that are compatible with the Skitude platform, most of them being the official applications of ski resorts.
It is a very active community. Thanks to the GPS Tracker that can log their runs, users have already logged activity at more than 1,200 ski resorts in 45 countries worldwide, and have been able to participate in more than 250 Challenges allowing them to win ski days, equipment like skis, boots or action cameras, and exclusive discounts.
The operation will allow consolidating the international project of 50 people, with offices in Girona, Lausanne and Oslo, and to continue researching to find dynamic solutions and improve the customer experience at ski resorts.
The shareholders of the company are comprised of the entrepreneurial partners Marc Bigas and David Huerva, Spanish investment funds, as well as the three Norwegian funds that own Skioo: Investinor, Canica and Norselab. Norselab counts the Olympic alpine ski champion Aksel Lund Svindal as an investor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005775/en/
Contact:
For more information: Àric Monterde +34-972-001-021 aric.monterde@skitude.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom